What is the current size and annual growth rate of the arthritic therapeutic market?
The arthritic therapeutic market size has grown strongly in recent years. It will grow from $68.1 $ billion in 2024 to $72.44 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing number of diagnosed patients, increasing awareness about the symptoms, increasing prevalence of obesity, improved diagnostic skills, and improved treatment outcomes.
The arthritic therapeutic market size is expected to see strong growth in the next few years. It will grow to $91.72 $ billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to improving healthcare infrastructure, government initiatives, supportive regulatory frameworks, focus on personalized medicine, and shift towards patient-centric healthcare approaches. Major trends in the forecast period include focus on biosimilar, shifting paradigm towards biologics, enhanced availability of biosimilars, preference for parenteral route, and growth of online pharmacies.
Get Your Free Sample of The Global Arthritic Therapeutic Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19297&type=smp
Which major factors have contributed to the expansion of the arthritic therapeutic market?
The increasing incidence of arthritis is expected to propel the growth of the arthritic therapeutic market going forward. Arthritis refers to a group of more than 100 conditions characterized primarily by joint pain and inflammation. The incidence of arthritis is growing due to an aging population, increased obesity rates, and lifestyle factors that contribute to joint stress and inflammation. Arthritis treatments alleviate symptoms, reduce inflammation, and improve joint function, enhancing the overall quality of life for those affected. For instance, in June 2024, according to a report published by the Australian Institute of Health and Welfare, an Australia-based government organization, approximately 514,000 people (2.0% of the population) were living with rheumatoid arthritis in 2022. Rheumatoid arthritis made up 2.0% of the total disease burden and represented 16% of the total burden for all musculoskeletal conditions in 2023. Therefore, the increasing incidence of arthritis is driving the growth of the arthritic therapeutic market.
How is the arthritic therapeutic market segmented?
The arthritic therapeuticmarket covered in this report is segmented –
1) By Drug Class: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Type: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout, Other Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab
2) By Interleukin Inhibitors: Interleukin-6 (IL-6) Inhibitors, Interleukin-1 (IL-1) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors
3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam
4) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
5) By Xanthine Oxidase Inhibitors: Allopurinol, Febuxostat
6) By Other Drug Classes: Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic DMARDs, Topical Analgesics, Opioid Pain Medications
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/arthritic-therapeutic-global-market-report
Who are the top competitors in the arthritic therapeutic market?
Major companies operating in the arthritic therapeutic market are Pfizer Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Pharma AB, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Zimmer Biomet Holdings Inc., UCB Pharma S.A., Incyte Corporation, Celltrion Inc., Mallinckrodt Pharmaceuticals, Genentech Inc., Anika Therapeutics Inc., Medac GmbH
Which key trends are expected to influence the arthritic therapeutic market in the coming years?
Major companies operating in the arthritis therapeutic market are focusing on developing innovative solutions such as biosimilar monoclonal antibody-based therapies, to enhance treatment efficacy and reduce costs. Biosimilar monoclonal antibody-based therapies are treatments designed to closely replicate and mimic the effectiveness of original monoclonal antibodies, offering similar therapeutic benefits at a potentially lower cost. For instance, in May 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, launched TOFIDENCE, an intravenous biosimilar monoclonal antibody formulation based on ACTEMRA. TOFIDENCE (tocilizumab-bavi) is developed to be a biosimilar to the reference drug ACTEMRA and is approved for treating moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Which regional trends are influencing the arthritic therapeutic market, and which area dominates the industry?
North America was the largest region in the arthritic therapeutic market in 2024. The regions covered in the arthritic therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Arthritic Therapeutic Market Report 2025 Offer?
The arthritic therapeutic market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Arthritic therapeutics refer to treatments designed to alleviate symptoms and improve quality of life for individuals with arthritis. This includes medications, physical therapy, and other interventions aimed at reducing pain, inflammation, and joint damage. These therapies can help manage various forms of arthritis, such as osteoarthritis and rheumatoid arthritis.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19297
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
